outcome of the HTA recorded and the impact of the biomarker test on the submission outcome was graded as high, medium or low according to its infl uence on the fi nal decision. These fi ndings were summarised, and 6 drugs were selected as case studies in order to identify key lessons relating to the risks, consequences, and ethical considerations of Diagnostic/Treatment partnering. RESULTS: The review identifi ed fi ve biomarkers in the fi ve treatment areas of: HIV, Gastrointestinal stromal tumour (GIST), Non-small cell lung cancer (NSCLC), Colorectal cancer (CRC), and Breast cancer. Markers Her2 and K-RAS had a high impact in all included submissions, with 100% and 63% of these submissions resulting in a positive recommendation. In contrast, marker EGFR had a lower impact (not mentioned in 4 out of 10 submissions), with 60% of these submissions being approved, and 40% rejected. The agencies most likely to reject a surrogate-outcome submission were PBAC (Australia) and SMC (Scotland) with rejection rates of 57% and 66% respectively, whereas CADTH accepted 100% of included submissions. CONCLUSIONS: Findings indicate fi rstly that substantially different evidence requirements exist between HTA bodies in the markets considered (e.g. differing accuracy acceptability thresholds, prospective/retrospective analysis and the importance of cost-effectiveness), and secondly there are several ethical considerations to the selection or deselection of patients for treatment.
PHP107 ECONOMIC EVIDENCE REQUIREMENTS: COMPARISON BETWEEN HTA AGENCIES AND IMPLICATIONS FOR MANUFACTURERS
Balvanyos J, Alnwick K, Proudfoot C Heron Evidence Development Ltd., London, UK OBJECTIVES: Mathematical models are required by decision makers to provide insight into pharmcoeconomic benefi ts associated with a product. It is therefore essential that manufacturers understand economic evidence requirements when submitting an application to a Health Technology Assessment (HTA) agency. METHODS: A literature search of economic recommendations from the following HTA agencies was conducted: CADTH (Canada), HAS (France), IQWiG (Germany), NICE (England), PBAC (Australia), PHARMAC (New Zealand) and SMC (Scotland). RESULTS: Cost-effectiveness analysis is considered the most relevant analytical technique across the English-speaking agencies with a preference for QALY-based analysis, in contrast to IQWiG which does not consider QALYs and utilities as central to their methods. Unlike other HTA agencies assessed, the French agency HAS does not currently require cost-effectiveness modelling in its decision-making process. EQ-5D is the most commonly used utility instrument, NICE being the most prescriptive agency in this regard. However, utilities mapped from disease-specifi c quality of life measures may be accepted and agencies such as PBAC and IQWiG express no formal preference between instruments. The third-party payer is the most commonly required perspective adopted across the English-speaking agencies while IQWiG and PBAC recommend a societal perspective in addition to the payer's perspective. This trend towards a broader, societal perspective may, however, be limited by uncertainties around measurement of wider costs. Sensitivity analyses are required by all agencies to explore uncertainty in the model. NICE and CADTH both favor a probabilistic approach while PBAC prefers univariate and multivariate analyses. Other agencies expect the manufacturer to justify their approach and choice. CONCLUSIONS: The recommendations of IQWiG and PBAC differ from the other selected agencies. Uniquely, in France the pharmaeconomic case is considered separately from the HTA process by the French Health Economists Association. These differences between agencies should be considered when planning evidence generation activities to support economic model development.
PHP108 CLINICAL EVIDENCE REQUIREMENTS: COMPARISON BETWEEN SEVEN HTA AGENCIES AND IMPLICATIONS FOR DRUG MANUFACTURERS
Balvanyos J, Alnwick K, Proudfoot C Heron Evidence Development Ltd., London, UK OBJECTIVES: Health Technology Assessment (HTA) agencies require various types and qualities of evidence for clinical effectiveness evaluations due to differences in health care systems and policies. It is essential for manufacturers to understand these requirements when submitting an application to each individual HTA agency. METHODS: A literature search of clinical recommendations from the following HTA agencies was conducted for comparison: CADTH (Canada), HAS (France), IQWiG (Germany), NICE (England), PBAC (Australia), PHARMAC (New Zealand) and SMC (Scotland). RESULTS: The choice of the optimal comparator is crucial to the outcome of the HTA. Almost all agencies prefer comparison versus the most frequently used interventions except for PBAC which requires comparison to the interventions most likely to be displaced. All HTA agencies are cautious in their interpretation of surrogate outcomes (SO) and require manufacturers to provide evidence linking the SO to fi nal patient-relevant outcomes. PBAC has notably developed a framework for assessing SOs and the impact of these on uncertainty in HTA submissions. Most agencies except for NICE clearly state their position on the defi nition and the use of SOs. All agencies recognize the value of observational studies in refl ecting real-world situations and providing long-term data although RCTs provide the key evidence on comparative effectiveness. Systematic reviews (SR) of clinical evidence are essential to present comparative effectiveness relative to all comparators. Contrary to most agencies, HAS prefers SRs but does not require them and bases its assessments mainly on pivotal clinical trials provided by the manufacturer. NICE and IQWiG also differ from the other agencies as they perform in-house SR in addition to the manufacturer's. CONCLUSIONS: The differences between agency requirements are subtle and mean that manufacturers need to put together a solid clinical evidence package needing very little adaptation to meet the seven country requirements. (HTA) . Part of the EUnetHTA Joint Action aims at reviewing methods used for the relative effectiveness assessment (REA) of pharmaceuticals and to develop, apply and fi eld-test tools and methods. As a fi rst step towards this goal, objectives, processes and methodologies used for REA by HTA organizations across Europe and other countries are summarised. This overview is crucial for the development of shared or common methodologies to be used in future REA across Europe. METHODS: Data were captured with a standardised data abstraction form. Data were initially abstracted from different types of literature (peer reviewed, grey literature, EU and national reports etc.). Where there were gaps in the data, telephone interviews were arranged with a relevant person at the respective HTA or reimbursement agency. RESULTS: Most European countries carry out some form of REA, however the defi nitions of the assessments in general are not consistent with the defi nition by the Pharmaceutical Forum. In addition the scope (inclusions of benefi t-risk analysis and/or a cost-effectiveness analysis), the process (timing, involvement of stakeholders and separation of assessment and appraisal phase) and the purpose (inform clinical decision-making, reimbursement and/or for pricing decision-making) of the assessments vary as well as the methods (such as inclusion of surrogate endpoints, composite endpoints and quality of life data and extrapolation of effi cacy data). Most agencies publish a guideline for the methodology used for REA however few publish them in English. CONCLUSIONS: A considerable number of European countries carry out REAs. However, the purpose and the methodology used vary across Europe. The reasons behind these differences need to be considered in the development of a common European methodology for REA.
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PHP110 PHYSICIANS' VIEWS OF THE RELATIVE IMPORTANCE OF SELECTED MEDICAL INNOVATIONS ON THE GREEK POPULATION HEALTH STATUS
Athanasakis K, Karampli E, Kyriopoulos J National School of Public Health, Athens, Greece OBJECTIVES: To identify the pharmaceutical and medical innovations that contributed mostly to the improvement of Greek population health status during the last three decades, according to physicians' views. METHODS: Building on the methodology by Fuchs and Sox, a questionnaire based survey was conducted on a representative sample of 500 Greek internists and general practitioners aged ≥50 years old. The study questionnaire was formulated by a panel of experts, with the use of the Delphi method and included one list of 22 pharmaceutical and a second list of 20 medical innovations. Physicians were asked to identify the seven more important and seven least important
